GetTopicDetailResponse(id=3e69e112b7, topicName=Evenity, introduction=Evenity, content=null, image=null, comments=5, allHits=822, url=https://h5.medsci.cn/topic?id=7112, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=88872, tagList=[TagDto(tagId=88872, tagName=Evenity)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1785878, encodeId=07ae1e8587837, content=<a href='/topic/show?id=3e69e112b7' target=_blank style='color:#2F92EE;'>#Evenity#</a>, objectTitle=骨質(zhì)疏松癥新藥Evenity（romosozumab）獲多國批準(zhǔn)上市，中國臨床試驗(yàn)也已開展, objectType=article, longId=195358, objectId=54c419535853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54c419535853, replyNumber=0, likeNumber=102, createdTime=2020-07-29, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54c419535853, moduleTitle=骨質(zhì)疏松癥新藥Evenity（romosozumab）獲多國批準(zhǔn)上市，中國臨床試驗(yàn)也已開展, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=54c419535853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785877, encodeId=a7081e85877ec, content=<a href='/topic/show?id=3e69e112b7' target=_blank style='color:#2F92EE;'>#Evenity#</a>, objectTitle=歐盟批準(zhǔn)將Evenity（romosozumab）用于治療絕經(jīng)后婦女的骨質(zhì)疏松癥, objectType=article, longId=184834, objectId=6c4b184834d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c4b184834d0, replyNumber=0, likeNumber=88, createdTime=2020-06-25, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c4b184834d0, moduleTitle=歐盟批準(zhǔn)將Evenity（romosozumab）用于治療絕經(jīng)后婦女的骨質(zhì)疏松癥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6c4b184834d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785876, encodeId=37ea1e858763d, content=<a href='/topic/show?id=3e69e112b7' target=_blank style='color:#2F92EE;'>#Evenity#</a>, objectTitle=安進(jìn)和優(yōu)時(shí)比的骨質(zhì)疏松藥物Evenity（romosozumab）喜獲歐洲藥品管理局推薦, objectType=article, longId=181603, objectId=223b18160372, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=223b18160372, replyNumber=0, likeNumber=105, createdTime=2020-07-29, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=223b18160372, moduleTitle=安進(jìn)和優(yōu)時(shí)比的骨質(zhì)疏松藥物Evenity（romosozumab）喜獲歐洲藥品管理局推薦, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=223b18160372)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785875, encodeId=14ab1e85875fc, content=<a href='/topic/show?id=3e69e112b7' target=_blank style='color:#2F92EE;'>#Evenity#</a>, objectTitle=Amgen在美國推出骨質(zhì)疏松癥藥物Evenity，年度定價(jià)為21900美元, objectType=article, longId=164437, objectId=1e9416443ec1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e9416443ec1, replyNumber=0, likeNumber=69, createdTime=2020-01-06, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e9416443ec1, moduleTitle=Amgen在美國推出骨質(zhì)疏松癥藥物Evenity，年度定價(jià)為21900美元, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1e9416443ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785874, encodeId=dc4a1e858747b, content=<a href='/topic/show?id=3e69e112b7' target=_blank style='color:#2F92EE;'>#Evenity#</a>, objectTitle=FDA批準(zhǔn)安進(jìn)/優(yōu)時(shí)比的抗骨質(zhì)疏松新藥Evenity上市, objectType=article, longId=159029, objectId=5e45159029d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e45159029d8, replyNumber=0, likeNumber=77, createdTime=2019-07-23, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e45159029d8, moduleTitle=FDA批準(zhǔn)安進(jìn)/優(yōu)時(shí)比的抗骨質(zhì)疏松新藥Evenity上市, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5e45159029d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
